Vascular Risk Therapies & Cognitive Decline
Cardiovascular Therapies Linked to slower Cognitive Decline and Reduced Alzheimer’s Pathology
Table of Contents
New research presented at the Alzheimer’s Association International Conference (AAIC) 2025 suggests that certain cardiovascular medications may play a protective role against cognitive decline and the underlying brain changes associated with alzheimer’s disease. The findings highlight the potential for managing cardiovascular health to impact brain health, though the role of antiplatelet drugs warrants further investigation.
Combination Therapies Show Promise for Cognitive Health
A study examining the association between the duration and combination of multiple cardiovascular therapy classes and the incidence of dementia revealed significant benefits.Researchers found that long-term users of multiple cardiovascular therapy classes experienced statistically significantly fewer dementia diagnoses compared to non-users.
Specifically, the use of two medication classes at baseline was associated with slower decline in global cognition. This protective effect extended to specific memory domains, including episodic, semantic, and working memory.
Impact on Neuropathology
In participants whose brains were examined post-mortem, the use of two medication classes was linked to several positive neuropathological findings.these included lower odds of atherosclerosis,reduced global Alzheimer’s disease (AD) pathology,and fewer tau tangles. Furthermore, this combination therapy was associated with lower odds of TDP-43 pathology, a protein aggregate implicated in various neurodegenerative diseases.
The study also indicated that baseline therapy with just one medication class was associated with slower semantic memory decline. In autopsied participants, this single medication class therapy was also linked to reduced tangles and lower odds of TDP-43 pathology.
Antiplatelets: A Complex Relationship with Dementia Risk
While the broader findings point towards the benefits of cardiovascular management, the research also identified a potential concern regarding antiplatelet medications. The study indicated that antiplatelet use was linked with more dementia diagnoses. This finding aligns with previous research that suggested while preventing dementia through cardiovascular drug pathways might be possible, the potential long-term negative cognitive effects of antiplatelets should be considered.
Swedish National Register Data supports Cardiovascular Intervention
Further supporting these findings, a case-control study utilizing data from Swedish national registers explored the association between the duration and combination of multiple cardiovascular therapy classes and incident dementia. This research, similar to the AAIC 2025 presented study, involved a large cohort of individuals aged 70 years and older.
The results demonstrated that long-term users of multiple cardiovascular therapy classes had significantly fewer dementia diagnoses compared to non-users. Notably, the use of antihypertensives in combination with diuretics, lipid-lowering drugs, and oral anticoagulants for at least five years was particularly related to fewer dementia diagnoses.
These studies collectively underscore the intricate relationship between cardiovascular health and cognitive function, suggesting that a comprehensive approach to managing cardiovascular risk factors through medication may offer a pathway to preserving cognitive health and perhaps mitigating the progression of neurodegenerative diseases like Alzheimer’s.
READ MORE: Meta-analysis Finds Apathy Highly Prevalent Across Lewy Body Dementia Spectrum
Click here for more coverage of AAIC 2025.
REFERENCES*
- Biswas R et al. Association of combination cardiovascular therapies with cognitive decline and neuropathologies. Presented at: 2025 Alzheimer’s Association International Conference; July 27-31; Toronto, Canada. Abstract 106195.
- Ding M, Wennberg AM, engström G, Modig K. Use of common cardiovascular disease drugs and risk of dementia: A case-control study in Swedish national register data. Alzheimers Dement. 2025;21(1):e14389. doi:10.1002/alz.14389